{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:18:15Z","timestamp":1787980695901,"version":"build-2784847793"},"reference-count":153,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/048snh465","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of mortality in patients with systemic sclerosis and a major clinical challenge due to its heterogeneous presentation and variable disease course. Reliable biomarkers may improve disease assessment, risk stratification, and therapeutic decision-making. This narrative review summarizes current evidence on established and emerging serum and molecular biomarkers in SSc-ILD and their potential clinical applications. Recent advances have shifted the focus from single-marker assessment toward integrated biomarker profiling, reflecting the complex pathogenesis of pulmonary fibrosis. KL-6 and surfactant protein D (SP-D) have been associated with pulmonary involvement and radiographic features of SSc-ILD. Inflammatory mediators, including interleukin-6 (IL-6), and autoantibodies such as anti-topoisomerase I (anti-Scl-70) have been associated with disease severity and an increased risk of pulmonary progression. Emerging biomarkers related to epithelial injury, extracellular matrix remodelling, and vascular dysfunction may provide additional insights into the biological mechanisms underlying SSc-ILD. Current evidence highlights the potential of circulating and molecular biomarkers to refine risk stratification and prognostic assessment in SSc-ILD. Prospective validation and methodological standardization remain necessary to determine their clinical utility and potential integration into personalized disease management.<\/jats:p>","DOI":"10.3390\/life16091420","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:02:27Z","timestamp":1787817747000},"page":"1420","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives"],"prefix":"10.3390","volume":"16","author":[{"given":"Rasha-Ioana","family":"R\u0103moiu-Shehada","sequence":"first","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Emanuela","family":"Mu\u0219etescu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian-Mihai","family":"Florescu","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesandra","family":"Florescu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina-Lucia","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic Sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2072","DOI":"10.1002\/hsr2.2072","article-title":"Neurological, Cardiac, Musculoskeletal, and Renal Manifestations of Scleroderma along with Insights into Its Genetics, Pathophysiology, Diagnostic, and Therapeutic Updates","volume":"7","author":"Prajjwal","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5301\/jsrd.5000209","article-title":"Gender Differences in Systemic Sclerosis: Relationship to Clinical Features, Serologic Status and Outcomes","volume":"1","author":"Peoples","year":"2016","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in Causes of Death in Systemic Sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in Systemic Sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in Mortality in Patients with Systemic Sclerosis over 40 Years: A Systematic Review and Meta-Analysis of Cohort Studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","article-title":"Major Lung Complications of Systemic Sclerosis","volume":"14","author":"Denton","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic Observations in Systemic Sclerosis (Scleroderma)","volume":"46","author":"Fries","year":"1969","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1759720X211032437","DOI":"10.1177\/1759720X211032437","article-title":"Interstitial Lung Disease Pathology in Systemic Sclerosis","volume":"13","author":"Konopka","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial Lung Disease Associated with Systemic Sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A Clinical and Serologic Comparison of African American and Caucasian Patients with Systemic Sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary Involvement in Systemic Sclerosis: Associations with Genetic, Serologic, Sociodemographic, and Behavioral Factors","volume":"57","author":"Mcnearney","year":"2007","journal-title":"Arthritis Care Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e8980","DOI":"10.1097\/MD.0000000000008980","article-title":"Clinical and Serological Features of Systemic Sclerosis in a Multicenter African American Cohort","volume":"96","author":"Morgan","year":"2017","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort","volume":"200","author":"Fretheim","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1093\/rheumatology\/keaf445","article-title":"A Screening Tool to Detect Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Score","volume":"64","author":"Bruni","year":"2025","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/art.43051","article-title":"Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis","volume":"77","author":"Hoa","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11926-022-01067-5","article-title":"Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis","volume":"24","author":"Khanna","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and Risk Factors for Death in Systemic Sclerosis: A Study from the EULAR Scleroderma Trials and Research (EUSTAR) Database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical Risk Assessment of Organ Manifestations in Systemic Sclerosis: A Report from the EULAR Scleroderma Trials and Research Group Database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current Perspectives on the Immunopathogenesis of Systemic Sclerosis","volume":"5","author":"Fuschiotti","year":"2016","journal-title":"ImmunoTargets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/ard.2010.130138","article-title":"Analysis of the Influence of PTPN22 Gene Polymorphisms in Systemic Sclerosis","volume":"70","author":"Gourh","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1002\/art.24958","article-title":"Polymorphisms in TBX21 and STAT4 Increase the Risk of Systemic Sclerosis: Evidence of Possible Gene\u2013Gene Interaction and Alterations in Th1\/Th2 Cytokines","volume":"60","author":"Gourh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/eci.11.31","article-title":"Targeting STAT4 in Systemic Sclerosis: A Promising New Direction","volume":"7","author":"Barnes","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/annrheumdis-2011-200901","article-title":"IRF5 Polymorphism Predicts Prognosis in Patients with Systemic Sclerosis","volume":"71","author":"Sharif","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2016.09.003","article-title":"The Role of MicroRNAs in the Pathogenesis of Autoimmune Diseases","volume":"15","author":"Chen","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00281-015-0507-3","article-title":"Environmental Risk Factors of Systemic Sclerosis","volume":"37","author":"Marie","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"984907","DOI":"10.3389\/fmed.2022.984907","article-title":"Exposure to Silica and Systemic Sclerosis: A Retrospective Cohort Study Based on the Canadian Scleroderma Research Group","volume":"9","author":"Muntyanu","year":"2022","journal-title":"Front. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/ard.53.8.506","article-title":"Increased Endothelin-1 Production in Fibroblasts Derived from Patients with Systemic Sclerosis","volume":"53","author":"Kawaguchi","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1051\/medsci\/20163202012","article-title":"Physiopathologie de La Scl\u00e9rodermie Syst\u00e9mique","volume":"32","author":"Allanore","year":"2016","journal-title":"M\u00e9decine\/Sciences"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.brainres.2016.12.026","article-title":"Effects of VPAC1 Activation in Nucleus Ambiguus Neurons","volume":"1657","author":"Gherghina","year":"2017","journal-title":"Brain Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B Cell Infiltration in Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated Serum BAFF Levels in Patients with Systemic Sclerosis: Enhanced BAFF Signaling in Systemic Sclerosis B Lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of Systemic Sclerosis: Current Understanding and New Insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1874312901408010029","article-title":"Systemic Sclerosis Is a Complex Disease Associated Mainly with Immune Regulatory and Inflammatory Genes","volume":"8","author":"Jin","year":"2014","journal-title":"Open Rheumatol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1038\/s41598-022-15062-4","article-title":"Combinations of Scleroderma Hallmark Autoantibodies Associate with Distinct Clinical Phenotypes","volume":"12","author":"Clark","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGF\u03b2-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.170.3.727","article-title":"Macrophage Production of Transforming Growth Factor Beta and Fibroblast Collagen Synthesis in Chronic Pulmonary Inflammation","volume":"170","author":"Khalil","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00002281-200111000-00010","article-title":"Transforming Growth Factor-\u03b2 and Connective Tissue Growth Factor: Key Cytokines in Scleroderma Pathogenesis","volume":"13","author":"Denton","year":"2001","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and Its Receptors in Fibrotic Diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar4230","article-title":"Scleroderma Pathogenesis: A Pivotal Role for Fibroblasts as Effector Cells","volume":"15","author":"Gilbane","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.lpm.2014.08.001","article-title":"Pathophysiology of Systemic Sclerosis: State of the Art in 2014","volume":"43","author":"Dumoitier","year":"2014","journal-title":"Presse M\u00e9dicale"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1759720X211032457","DOI":"10.1177\/1759720X211032457","article-title":"Role of Autoantibodies in the Diagnosis and Prognosis of Interstitial Lung Disease in Autoimmune Rheumatic Disorders","volume":"13","author":"Kuwana","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kowalska-K\u0119pczy\u0144ska, A. (2022). Systemic Scleroderma\u2014Definition, Clinical Picture and Laboratory Diagnostics. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092299"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as Predictive Tools in Systemic Sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of Disease-Associated and Other Nuclear Autoantibodies in Patients of the German Network for Systemic Scleroderma: Correlation with Characteristic Clinical Features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers","volume":"64","author":"Cavazzana","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the Profile of the EUSTAR Cohort: An Analysis of the EULAR Scleroderma Trials and Research Group Database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/imr.13390","article-title":"Pathogenic Role of Anti-nuclear Autoantibodies in Systemic Sclerosis: Insights from Other Rheumatic Diseases","volume":"328","author":"Huizinga","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of Interstitial Lung Disease in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2622","article-title":"Diagnostic Value of Anti-Topoisomerase I Antibodies in a Large Monocentric Cohort","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kez005","article-title":"Prognostic Properties of Anti-Topoisomerase Antibodies in Patients Identified by the ACR\/EULAR 2013 Systemic Sclerosis Criteria","volume":"58","author":"Boonstra","year":"2019","journal-title":"Rheumatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/art.10977","article-title":"Correlation of Serum Anti-DNA Topoisomerase I Antibody Levels with Disease Severity and Activity in Systemic Sclerosis","volume":"48","author":"Hu","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The Clinical Relevance of Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and Organ Involvement in Patients with Limited Cutaneous Systemic Sclerosis and Anti-Topoisomerase-I Antibodies: Determined by Skin Subtype or Auto-Antibody Subtype? A Long-Term Follow-up Study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2397198319894851","article-title":"Circulating Biomarkers of Systemic Sclerosis\u2014Interstitial Lung Disease","volume":"5","author":"Fretheim","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.3390\/cimb45100490","article-title":"Biomarkers in Systemic Sclerosis: An Overview","volume":"45","author":"Confalonieri","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Utsunomiya, A., Oyama, N., and Hasegawa, M. (2020). Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113388"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial Lung Disease in Connective Tissue Disease\u2014Mechanisms and Management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive Clinical Phenotype of Anti-Centromere Antibody-Positive Diffuse Systemic Sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive Value of Antinuclear Autoantibodies: The Lessons of the Systemic Sclerosis Autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.semarthrit.2015.06.011","article-title":"Survival in Systemic Sclerosis\u2013Pulmonary Arterial Hypertension by Serum Autoantibody Status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry","volume":"45","author":"Hinchcliff","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.autrev.2009.02.002","article-title":"Anti-RNA Polymerase III Antibodies: A Marker of Systemic Sclerosis with Rapid Onset and Skin Thickening Progression","volume":"8","author":"Cavazzana","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.38994","article-title":"Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients with Anti\u2013RNA Polymerase III Autoantibodies","volume":"67","author":"Hamaguchi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of Anti-RNA Polymerase III Autoantibodies and Cancer in Scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/rheumatology\/keab735","article-title":"Association between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry","volume":"61","author":"Hoa","year":"2022","journal-title":"Rheumatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of Autoantibody Status and Clinical Features Associated with Cancer Risk and Cancer-Associated Scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear Antibodies in Systemic Sclerosis: An Update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good Outcome of Interstitial Lung Disease in Patients with Scleroderma Associated to Anti-PM\/Scl Antibody","volume":"44","author":"Pallisa","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and Serologic Correlates of Anti-PM\/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients","volume":"66","author":"Hudson","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_74","first-page":"189","article-title":"The Prevalence and Significance of Anti-PM\/Scl Antibodies in Systemic Sclerosis","volume":"28","author":"Wielosz","year":"2021","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-Specificity Anti-Ku Antibodies in an International Cohort of 2140 Systemic Sclerosis Subjects","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2169\/internalmedicine.41.1096","article-title":"Clinical Significance of Anti-Ku Autoantibodies\u2014A Serologic Marker of Overlap Syndrome?","volume":"41","author":"Mimori","year":"2002","journal-title":"Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory Myopathies with Anti-Ku Antibodies","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical Significance of Antibodies to Ro52\/TRIM21 in Systemic Sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.chest.2025.05.036","article-title":"Association of Anti-Ro52 Seropositive Interstitial Lung Disease with a Higher Risk of Disease Progression and Mortality","volume":"168","author":"Imai","year":"2025","journal-title":"Chest"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12016-021-08911-z","article-title":"Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome When Associated with Interstitial Lung Disease in Systemic Sclerosis and Autoimmune Myositis","volume":"63","author":"Chan","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"103536","DOI":"10.1016\/j.autrev.2024.103536","article-title":"Prevalence of Anti-Ro52-KDa\/SSA (TRIM21) Antibodies and Associated Clinical Phenotype in Systemic Sclerosis: Data from a French Cohort, a Systematic Review and Meta-Analysis","volume":"23","author":"Martel","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 Positivity Is Associated with Progressive Interstitial Lung Disease in Systemic Sclerosis\u2014An Exploratory Study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e002076","DOI":"10.1136\/bmjresp-2023-002076","article-title":"Association of Anti-Ro52 Autoantibody with Interstitial Lung Disease in Autoimmune Diseases: A Systematic Review and Meta-Analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fritzler, M.J., Bentow, C., Beretta, L., Palterer, B., Perurena-Prieto, J., Sanz-Mart\u00ednez, M.T., Guillen-Del-Castillo, A., Mar\u00edn, A., Fonollosa-Pla, V., and Callejas-Moraga, E. (2023). Anti-U11\/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071257"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of Anti-Eukaryotic Initiation Factor-2B, Anti-RuvBL1\/2 and Anti-Synthetase Antibodies in Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100272","DOI":"10.1016\/j.jtauto.2025.100272","article-title":"Autoantibodies in Systemic Sclerosis: From Disease Bystanders to Pathogenic Players","volume":"10","author":"Chepy","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100049","DOI":"10.1016\/j.jtauto.2020.100049","article-title":"Autoantibodies as Biomarkers for Interstitial Lung Disease in Idiopathic Inflammatory Myositis and Systemic Sclerosis: The Case of Anti-EIF2B Antibodies","volume":"3","author":"Ceribelli","year":"2020","journal-title":"J. Transl. Autoimmun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1093\/rheumatology\/kead060","article-title":"Detection of Anti-EIF2B Autoantibodies in Systemic Sclerosis by Immunoprecipitation-Mass Spectrometry","volume":"62","author":"Vulsteke","year":"2023","journal-title":"Rheumatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1523-1747.2003.12028.x","article-title":"The Prevalence and Clinical Significance of Anti-U1 RNA Antibodies in Patients with Systemic Sclerosis","volume":"120","author":"Asano","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/rheumatology\/kez230","article-title":"Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease: Review of the Literature","volume":"58","author":"Bonhomme","year":"2019","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2020.01990","article-title":"Interstitial Lung Disease in Patients with Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)","volume":"11","author":"Khedoe","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-Related Interstitial Lung Disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"00158","DOI":"10.1183\/23120541.00158-2025","article-title":"Circulating Biomarkers in Subjects with Progressive Pulmonary Fibrosis: Data from the INBUILD Trial","volume":"12","author":"Maher","year":"2026","journal-title":"ERJ Open Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.iac.2023.01.012","article-title":"Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease","volume":"43","author":"Pugashetti","year":"2023","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"152366","DOI":"10.1016\/j.semarthrit.2024.152366","article-title":"KL6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)","volume":"65","author":"Santos","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","article-title":"Serum KL-6 Levels Reflect the Severity of Interstitial Lung Disease Associated with Connective Tissue Disease","volume":"21","author":"Lee","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0925-4439(98)00079-9","article-title":"Surfactant Proteins A and D: Disease Markers","volume":"1408","author":"Kuroki","year":"1998","journal-title":"Biochim. Biophys. Acta (BBA) -Mol. Basis Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_99","first-page":"1112","article-title":"Comparative Study of Serum Surfactant Protein-D and KL-6 Concentrations in Patients with Systemic Sclerosis as Markers for Monitoring the Activity of Pulmonary Fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5","article-title":"Clinical Significance of Surfactant Protein D as a Serum Marker for Evaluating Pulmonary Fibrosis in Patients with Systemic Sclerosis","volume":"44","author":"Asano","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/jtd.2017.02.48","article-title":"Serum KL-6 and Surfactant Protein-D as Monitoring and Predictive Markers of Interstitial Lung Disease in Patients with Systemic Sclerosis and Mixed Connective Tissue Disease","volume":"9","author":"Yamakawa","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/art.22559","article-title":"CCL18 as an Indicator of Pulmonary Fibrotic Activity in Idiopathic Interstitial Pneumonias and Systemic Sclerosis","volume":"56","author":"Prasse","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High Level of Chemokine CCL18 Is Associated with Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis","volume":"150","author":"Garen","year":"2016","journal-title":"Chest"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC Chemokine Ligand-18 Predicts Lung Disease Worsening in Systemic Sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-015-0506-4","article-title":"Update on Biomarkers in Systemic Sclerosis: Tools for Diagnosis and Treatment","volume":"37","author":"Affandi","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-010-1610-4","article-title":"Serum Chemokine and Cytokine Levels as Indicators of Disease Activity in Patients with Systemic Sclerosis","volume":"30","author":"Hasegawa","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients with Early Systemic Sclerosis: Data from Two Independent Cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-Wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis","volume":"370","author":"Affandi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.revmed.2009.05.001","article-title":"Augmentation de CXCL10 Dans Le S\u00e9rum Au Cours de La Pneumopathie Interstitielle de La Scl\u00e9rodermie Syst\u00e9mique","volume":"30","author":"Tiev","year":"2009","journal-title":"Rev. Med. Interne"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 ( ) and CCL2 ( ) Chemokines in Systemic Sclerosis a Longitudinal Study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ard.2003.018705","article-title":"Up Regulated Expression of Fractalkine\/CX3CL1 and CX3CR1 in Patients with Systemic Sclerosis","volume":"64","author":"Hasegawa","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","article-title":"Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, Which Mediates Both Leukocyte Migration and Adhesion","volume":"91","author":"Imai","year":"1997","journal-title":"Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e0206545","DOI":"10.1371\/journal.pone.0206545","article-title":"Augmented Concentrations of CX3CL1 Are Associated with Interstitial Lung Disease in Systemic Sclerosis","volume":"13","author":"Weigt","year":"2018","journal-title":"PLoS ONE"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00296-019-04402-9","article-title":"Serum YKL-40 and IL-6 Levels Correlate with Ultrasound Findings of Articular and Periarticular Involvement in Patients with Systemic Sclerosis","volume":"39","author":"Karalilova","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3899\/jrheum.111423","article-title":"Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy","volume":"39","author":"Muangchan","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"INTERLEUKIN-6: From Basic Science to Medicine\u201440 Years in Immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum Levels of Interleukin-6 and Interleukin-10 Correlate with Total Skin Thickness Score in Patients with Systemic Sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis","volume":"40","author":"Sestini","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting Interleukin-6 Signaling in Clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/03009740510018598","article-title":"High Serum Levels of YKL-40 in Patients with Systemic Sclerosis Are Associated with Pulmonary Involvement","volume":"34","author":"Johansen","year":"2005","journal-title":"Scand. J. Rheumatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.matbio.2018.02.007","article-title":"Emerging Insights into the Role of Matrix Metalloproteases as Therapeutic Targets in Fibrosis","volume":"68\u201369","author":"Afratis","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-0625.2011.01321.x","article-title":"Elevated MMP-7 Levels in Patients with Systemic Sclerosis: Correlation with Pulmonary Involvement","volume":"20","author":"Moinzadeh","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.matbio.2007.07.001","article-title":"Control of Matrix Metalloproteinase Catalytic Activity","volume":"26","author":"Ra","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/ar1454","article-title":"Elevated Matrix Metalloproteinase-9 in Patients with Systemic Sclerosis","volume":"7","author":"Kim","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2011-200837","article-title":"Increased Serum Levels and Tissue Expression of Matrix Metalloproteinase-12 in Patients with Systemic Sclerosis: Correlation with Severity of Skin and Pulmonary Fibrosis and Vascular Damage","volume":"71","author":"Manetti","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive Protein with High Disease Activity in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1346-8138.2010.00883.x","article-title":"Serum Interleukin-6 Level Is Reflected in Elevated High-sensitivity C-reactive Protein Level in Patients with Systemic Sclerosis","volume":"37","author":"Ohtsuka","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and Autoantibodies Define Scleroderma Subtypes and Risk in African and European Americans and Suggest a Role for Molecular Mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2021-219884","article-title":"Comprehensive Analysis of the Major Histocompatibility Complex in Systemic Sclerosis Identifies Differential HLA Associations by Clinical and Serological Subtypes","volume":"80","author":"Kerick","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"913196","DOI":"10.3389\/fgene.2022.913196","article-title":"Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes","volume":"13","author":"Hanson","year":"2022","journal-title":"Front. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","article-title":"Frequency of Circulating Topoisomerase-I-Specific CD4 T Cells Predicts Presence and Progression of Interstitial Lung Disease in Scleroderma","volume":"18","author":"Fava","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial Lung Disease in Systemic Sclerosis: Where Do We Stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Randomised Controlled, Double-Blind, Parallel Group Trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/1346-8138.14669","article-title":"Prediction of Therapeutic Response before and during i.v. Cyclophosphamide Pulse Therapy for Interstitial Lung Disease in Systemic Sclerosis: A Longitudinal Observational Study","volume":"45","author":"Sumida","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in Systemic Sclerosis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (FaSScinate): A Phase 2, Randomised, Controlled Trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/rheumatology\/kead234","article-title":"Prognostic and Predictive Markers of Systemic Sclerosis-Associated Interstitial Lung Disease in a Clinical Trial and Long-Term Observational Cohort","volume":"63","author":"Ghuman","year":"2024","journal-title":"Rheumatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A Multicenter, Open-Label, Comparative Study of B-Cell Depletion Therapy with Rituximab for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"214013","DOI":"10.1155\/2011\/214013","article-title":"B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence","volume":"2011","author":"Daoussis","year":"2011","journal-title":"Int. J. Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with Rituximab in Scleroderma: Results from a 1-Year, Proof-of-Principle Study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of Patients with Systemic Sclerosis Treated with Rituximab in Contemporary Practice: A Prospective Cohort Study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and Mycophenolate Mofetil Combination in Patients with Interstitial Lung Disease (EVER-ILD): A Double-Blind, Randomised, Placebo-Controlled Trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus Intravenous Cyclophosphamide in Patients with Connective Tissue Disease-Associated Interstitial Lung Disease in the UK (RECITAL): A Double-Blind, Double-Dummy, Randomised, Controlled, Phase 2b Trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An Open-Label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-Associated Interstitial Lung Disease: The LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/acr2.70126","article-title":"Combining Pirfenidone with Mycophenolate Mofetil for Systemic Sclerosis\u2013Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","volume":"7","author":"Khanna","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","article-title":"Nintedanib in Progressive Interstitial Lung Diseases: Data from the Whole INBUILD Trial","volume":"59","author":"Flaherty","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined Anti-Fibrotic and Anti-Inflammatory Properties of JAK-Inhibitors on Macrophages in Vitro and in Vivo: Perspectives for Scleroderma-Associated Interstitial Lung Disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e159566","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib Blocks IFN-Regulated Biomarker Genes in Skin Fibroblasts and Keratinocytes in a Systemic Sclerosis Trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1420\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:26:54Z","timestamp":1787977614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":153,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091420"],"URL":"https:\/\/doi.org\/10.3390\/life16091420","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}